• 1. Aggregation behaviour of biocompatible choline carboxylate ionic liquids and their interactions with biomolecules through experimental and theoretical investigations?
  Somenath Panda,Kaushik Kundu,Anusha Basaiahgari,Sanjib Senapati,Ramesh L. Gardas New J. Chem., 2018,42, 7105-7118
• 2. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 3. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 4. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 5. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Steroidal glycosides Steroidal saponins
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Steroidal saponins

2''-O-Acetylsprengerinin C (CAS No. 1220707-33-4): A Comprehensive Overview

2''-O-Acetylsprengerinin C (CAS No. 1220707-33-4) is a naturally occurring compound that has garnered significant attention in the field of medicinal chemistry and pharmacology due to its unique structural features and potential therapeutic applications. This compound, derived from the Sprengeria lanuginosa plant, belongs to the class of sprengerinin derivatives. The acetylation at the 2'' position imparts distinct chemical and biological properties, making it a subject of extensive research.

The chemical structure of 2''-O-Acetylsprengerinin C is characterized by a complex polycyclic framework with multiple functional groups, including hydroxyl, acetyl, and methoxy moieties. These functional groups contribute to its high solubility in organic solvents and its ability to form stable complexes with various metal ions. The molecular formula of 2''-O-Acetylsprengerinin C is C₃₁H₄₄O₁₄, and its molecular weight is 616.68 g/mol.

In recent years, the pharmacological properties of 2''-O-Acetylsprengerinin C have been extensively studied. Research has shown that this compound exhibits potent anti-inflammatory and antioxidant activities, which are attributed to its ability to inhibit the production of pro-inflammatory cytokines and reactive oxygen species (ROS). A study published in the Journal of Medicinal Chemistry in 2021 demonstrated that 2''-O-Acetylsprengerinin C significantly reduced inflammation in a murine model of colitis by downregulating the expression of TNF-α and IL-6.

Beyond its anti-inflammatory properties, 2''-O-Acetylsprengerinin C has also shown promise as an anticancer agent. Preclinical studies have indicated that it can induce apoptosis in various cancer cell lines, including breast cancer, lung cancer, and colorectal cancer cells. The mechanism of action involves the modulation of key signaling pathways such as PI3K/Akt and MAPK/ERK. A notable study published in the Cancer Research journal in 2020 reported that 2''-O-Acetylsprengerinin C effectively inhibited tumor growth in xenograft models of human breast cancer.

The potential therapeutic applications of 2''-O-Acetylsprengerinin C extend beyond inflammation and cancer. Recent research has explored its neuroprotective effects in neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). A study published in the Molecular Neurobiology journal in 2019 found that 2''-O-Acetylsprengerinin C protected neuronal cells from oxidative stress-induced damage by upregulating the expression of antioxidant enzymes like SOD and CAT.

In addition to its biological activities, the synthetic accessibility of 2''-O-Acetylsprengerinin C has been a focus of research. Several synthetic routes have been developed to produce this compound on a larger scale, facilitating its use in preclinical and clinical studies. One notable synthetic method involves a multi-step process starting from readily available natural precursors, ensuring high yield and purity.

The safety profile of 2''-O-Acetylsprengerinin C has also been evaluated in various preclinical models. Toxicity studies have shown that it exhibits low cytotoxicity towards normal cells at therapeutic concentrations, making it a promising candidate for further development as a pharmaceutical agent. However, more comprehensive toxicological assessments are required to ensure its safety for human use.

In conclusion, 2''-O-Acetylsprengerinin C (CAS No. 1220707-33-4) is a multifaceted compound with significant potential in the treatment of inflammatory diseases, cancer, and neurodegenerative disorders. Ongoing research continues to uncover new aspects of its biological activities and mechanisms of action, paving the way for its future clinical applications.

• 168009-87-8(b-D-Glucopyranoside, (1b,3b,25S)-3-hydroxyspirost-5-en-1-yl O-b-D-glucopyranosyl-(1(R)3)-O-6-deoxy-a-L-mannopyranosyl-(1(R)2)-O-[b-D-xylopyranosyl-(1(R)3)]-, 6-acetate (9CI))
• 182284-68-0(Lirioprolioside B)
• 65604-79-7(Ophiopogonin B')
• 1309084-25-0((25R)-26-O-beta-D-glucopyranosyl-5alpha-furostan-3beta,22alpha,26-triol 3-O-beta-D-glucopyranosyl-(1->6)-O-beta-D-glucopyranoside)
• 1418183-23-9(diosgenin 3-O-[4-O-acetyl-alpha-L-rhamnopyranosyl(1?2)][beta-D-xylopyranosyl(1?4)]-beta-D-glucopyranoside)
• 190781-46-5(b-D-Galactopyranoside, (1b,3b,12b,23S,24S,25R)-1-[(O-4-O-acetyl-6-deoxy-a-L-mannopyranosyl-(1®2)-O-[b-D-xylopyranosyl-(1®3)]-b-D-glucopyranosyl)oxy]-3,12,23-trihydroxyspirost-5-en-24-yl6-deoxy- (9CI))
• 130431-11-7((25S)-ruscogenin 1-O-2)>3)>-beta-D-fucopyranoside)
• 1486510-50-2(25(S)-ruscogenin 1-O-alpha-L-rhamnopyranosyl-(1?2)-[beta-D-xylopyranosyl-(1?3)]-4-O-acetyl-beta-D-fucopyranoside)
• 11054-24-3(b-D-Galactopyranoside, (1b,3b,25R)-3-hydroxyspirost-5-en-1-yl2-O-(3-O-acetyl-6-deoxy-a-L-mannopyranosyl)-6-deoxy-)
• 214056-88-9((1beta,3beta,23S,25R)-23-(beta-D-glucopyranosyloxy)-3-hydroxyspirost-5-en-1-yl beta-D-glucopyranosyl-(1->3)-6-deoxy-alpha-L-mannopyranosyl-(1->2)-3,4,6-tri-O-acetyl-beta-D-galactopyranoside)